Docetaxel and Flavopiridol in Treating Patients With Locally Advanced or Metastatic Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00020332
Recruitment Status : Completed
First Posted : January 27, 2003
Last Update Posted : June 17, 2013
Information provided by:
National Cancer Institute (NCI)

July 11, 2001
January 27, 2003
June 17, 2013
October 2000
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00020332 on Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
Docetaxel and Flavopiridol in Treating Patients With Locally Advanced or Metastatic Breast Cancer
A Phase I/II Trial of Docetaxel Followed by Infusional Flavopiridol Over 72 Hours in Patients With Previously Treated Locally Advanced or Metastatic Breast Cancer

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.

PURPOSE: Phase I/II trial to study the effectiveness of combination chemotherapy in treating patients who have locally advanced or metastatic breast cancer.


  • Determine the maximum tolerated dose of docetaxel and flavopiridol in patients with previously treated locally advanced or metastatic breast cancer.
  • Determine the dose-limiting toxicity, toxicity profile, and pharmacokinetics of this regimen in these patients.
  • Determine the activity of this regimen in these patients.
  • Determine the objective response rate in patients treated with this regimen.
  • Determine immune dysfunction produced by this regimen as measured by lymphocyte subpopulations, including T-cell activation/memory subsets and natural killer cell/lymphokine-activated killer cell functional subsets in these patients.
  • Determine the ability of positron emission tomography scanning to predict response in patients treated with this regimen.
  • Determine the response duration, time to treatment failure, and overall survival of patients treated with this regimen.
  • Determine the quality of life of patients treated with this regimen.
  • Determine whether this regimen is associated with the development of a prothrombotic state in these patients.

OUTLINE: This is a dose-escalation study.

Patients receive docetaxel IV over 1 hour on day 1 followed by flavopiridol IV over 1 hour or IV continuously on days 2-4. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity.

Sequential dose escalation of docetaxel is preceded or followed by sequential dose escalation of flavopiridol. Cohorts of 3-6 patients receive escalating doses of docetaxel preceded or followed by escalating doses of flavopiridol until the maximum tolerated dose (MTD) of the combination is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, 22 additional patients are accrued to receive flavopiridol and docetaxel at the recommended phase II dose.

Quality of life is assessed at baseline, every 3 courses during study, and then at completion of study.

PROJECTED ACCRUAL: A total of 49 patients (27 for phase I and 22 for phase II) will be accrued for this study within 2 years.

Phase 1
Phase 2
Primary Purpose: Treatment
Breast Cancer
  • Drug: alvocidib
  • Drug: docetaxel
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Not Provided
Not Provided
March 2003
Not Provided


  • Histologically confirmed stage III or IV adenocarcinoma of the breast
  • Phase I:

    • Evaluable disease allowed
  • Phase II:

    • At least 1 site of measurable disease
  • No bone metastasis as only site of disease
  • No carcinomatous meningitis or brain metastases
  • Hormone receptor status:

    • Not specified



  • 18 and over


  • Male or female

Menopausal status:

  • Not specified

Performance status:

  • ECOG 0-2

Life expectancy:

  • Not specified


  • Granulocyte count at least 1,500/mm^3
  • Platelet count at least 100,000/mm^3
  • No active coagulopathy requiring therapeutic anticoagulation


  • Bilirubin no greater than upper limit of normal (ULN)
  • SGOT no greater than 1.5 times ULN
  • Alkaline phosphatase no greater than 2.5 times ULN
  • No Gilbert's disease


  • Creatinine no greater than 1.5 mg/dL


  • Left ventricular ejection fraction at least 50% without clinical signs or symptoms of heart failure
  • No uncontrolled hypertension (sustained systolic blood pressure (BP) greater than 180 mm Hg or diastolic BP greater than 100 mm Hg)
  • No uncontrolled cardiac arrhythmia
  • No myocardial infarction within the past year
  • No significant ischemia or valvular heart disease


  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • No medical or psychiatric condition that would increase risk
  • No other malignancy within the past 5 years except carcinoma in situ of the cervix or nonmelanomatous skin cancer
  • No grade 2 or greater peripheral neuropathy
  • No diabetes mellitus with a fasting blood sugar greater than 200 mg/dL
  • No active unresolved infection
  • No serious concurrent medical illness
  • No history of hypersensitivity reaction to products containing polysorbate 80 (Tween 80)


Biologic therapy:

  • Not specified


  • No prior flavopiridol
  • Prior adjuvant chemotherapy for advanced disease allowed if within 6 months of diagnosis of metastatic disease
  • At least 4 weeks since prior chemotherapy (6 weeks for nitrosourea or 8 weeks for UCN-01) and recovered
  • Phase I:

    • Any number of prior chemotherapy regimens for metastatic carcinoma of the breast allowed
  • Phase II:

    • No more than 2 prior chemotherapy regimens for metastatic carcinoma of the breast

Endocrine therapy:

  • Prior hormonal therapy in the metastatic or adjuvant setting allowed
  • At least 2 weeks since prior hormonal therapy and no evidence of disease improvement by radiography after therapy
  • Concurrent corticosteroids allowed if for study premedication or hypersensitivity reactions/adverse events


  • No concurrent radiotherapy


  • Not specified


  • No other concurrent antineoplastic therapies
  • No other concurrent investigational drugs
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
United States
Not Provided
Not Provided
Not Provided
Not Provided
National Cancer Institute (NCI)
Not Provided
Study Chair: Antoinette R. Tan, MD National Cancer Institute (NCI)
National Cancer Institute (NCI)
July 2002

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP